Idenix Pharmaceuticals: Building a Leading Antiviral Franchise. Jean-Pierre Sommadossi Chairman and Chief Executive Officer Spring 2006
|
|
- Angelica Singleton
- 5 years ago
- Views:
Transcription
1 Idenix Pharmaceuticals: Building a Leading Antiviral Franchise Jean-Pierre Sommadossi Chairman and Chief Executive Officer Spring 2006
2 Safe Harbor This presentation includes forward-looking statements about Idenix and its business, including without limitation, statements regarding drug discovery, research and clinical development, regulatory approval processes and commercialization activities. These forward-looking statements are subject to risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These risks and uncertainties are detailed in our filings with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this presentation and, except as required by law, we undertake no obligation to update such statements. 2 2
3 Idenix Building a Leading Antiviral Franchise Mission Products Alliance Global Structure Financial Position Founded in 1998 to discover, develop and commercialize innovative antiviral drugs addressing unmet medical needs in large and growing markets 3 clinical stage drug candidates Novartis global alliance enhances commercial and financial position More than 230 employees at 3 locations in U.S. and Europe Strong balance sheet 3 3
4 Idenix/Novartis Strategic Alliance Landmark Biotech/Pharma Deal 4 Consummated in May 2003, equity purchase and license agreement Novartis licensed: HBV drug program in May 2003 Valopicitabine (NM283) in March 2006 For licensed programs: Novartis reimburses 100% of development costs on goforward basis from point of license License fees and milestone payments Co-promote and profit split in US and 5 major EU countries First right of refusal to Idenix pipeline Novartis holds 56% of Idenix Maintained equity position through follow-on offering - $81M Standstill until May of 9 board seats 4
5 Novartis Licensing Terms Hepatitis B Licensed May 2003 $110 million in potential licensing fees and regulatory milestone payments - Upfront licensing payment of $75 million - Upfront to $35 million in regulatory milestones Sales milestones Co-promotion and profit split in U.S. and 5 major EU countries for all licensed products In ROW, payments to Idenix based on product sales Hepatitis C Licensed March 2006 $550 in potential license fees and regulatory milestone payments $25 million milestone received June 2004 Up to $70 million in license fees ($25M paid in March 2006, remainder due upon initiation of phase III trials in US) Up to $455 million in regulatory milestones Sales milestones Co-promotion and profit split in U.S. and 5 major EU countries for all licensed products In ROW, payments to Idenix based on product sales 5 5
6 Building a Leading Antiviral Franchise NDA Filed for Lead Drug Candidate Indication Program Preclinical Phase Ib/IIa Phase IIb Phase III NDA HBV Telbivudine (LdT) Valtorcitabine (val-ldc) Valopicitabine HCV (NM283) NV-08 HIV NV-05 90% of antiviral nucleosides with successful Phase I/II results have led to NDA approval 1 6 Source: 1 International Antiviral News Vol.7, No.7 and Vol.8 No.1 (01/00) 6
7 Telbivudine Phase III GLOBE Study Largest Pivotal Hepatitis B Clinical Trial Two-year international phase III head-to-head trial vs. lamivudine Ongoing and fully enrolled with 1,367 patients in intent-to-treat population One-year results completed and being used for worldwide marketing applications Superior to lamivudine on all key virologic endpoints Achieved primary and secondary endpoints US NDA filed by Idenix in 2005 Marketing applications by Novartis submitted in the European Union (EU) and key Asian markets in 1Q
8 Telbivudine vs Lamivudine in Chinese HBV Patients Significantly Greater Antiviral and Clinical Efficacy vs. Lamivudine Pooled data includes both e-positive and e-negative patients Efficacy at week 52 Number of patients HBV DNA (mean log 10 ) HBV DNA non-detectable by PCR (%) Therapeutic response (%) ALT normalization (%) HBeAg loss (%) HBeAg seroconversion (%) Resistance (%) Telbivudine HBV DNA <5 log 10 copies/ml with HBeAg loss or ALT normalization HBeAg-positive patients only Lamivudine P value <0.001 <0.001 < Hou, J-L. et. al HEPA Poster 180 8
9 Telbivudine vs. Adefovir Phase IIIb Clinical Trial Superior to Adefovir on Primary Efficacy Endpoint: Results at Week 24 HBeAg-positive patients N HBV DNA decrease from baseline (mean log 10 )* HBV DNA <5 log 10 (%) HBV DNA PCR-neg (%) ALT normalized (%) HBeAg loss (%) Telbivudine Adefovir * Primary efficacy endpoint percent of patients with HBV DNA level <5 log 10 (AASLD & APASL guideline) COBAS PCR assay limit <300 copies/ml Color designates p< Chan. et. al EASL Abstract 9
10 Telbivudine To Treat Hepatitis B Comprehensive Product Profile Upon Launch Trial Design Status Patients with decompensated cirrhosis (liver failure) Phase III Telbivudine vs. Adefovir Phase IIIb Lamivudine Switch Phase IIIb Lamivudine-resistant patients Phase IIIb 240 patients Two-year study 120 HBeAg-positive patients One-year study 240 HBeAg+ and HBeAg- patients who have received 3-12 months of lamivudine, randomized to continue lamivudine or switch to telbivudine. One-year study patients Telbivudine plus adefovir vs. adefovir alone One-year study Over 130 patients enrolled, trial ongoing Full enrolled, ongoing Fully enrolled, ongoing Planned 10 10
11 11 The US Rx Market for HBV Nucleosides Has Nearly Tripled in the Last 3 Years HBV Weekly Rx Trend 6,000 5, growth = 32.7% 4, growth = 38.4% 3,000 2,000 1,000 0 Source: IMS Weekly Oral Nucleoside Rx Data through December, TRx 2005 growth = 30.4% Dec-05 Oct-05 Aug-05 Jun-05 Apr-05 Feb-05 Dec-04 Oct-04 Aug-04 Jun-04 Apr-04 Feb-04 Dec-03 Oct-03 Aug-03 Jun-03 Apr-03 Feb-03 Dec-02 Oct-02 Aug-02
12 Hepatitis C Current Development Landscape NM283 is Most Advanced Specifically Targeting HCV Replication Candidate Name Target/Type Company Status Nucleoside Polymerase Inhibitors Valopicitabine (NM283) Nucleoside analog R-1626 Nucleoside analog Non-nucleoside Polymerase Inhibitors JTK-003 Non-nucleoside HCV-796 Non-nucleoside Protease Inhibitors VX-950 Protease inhibitor SCH Protease inhibitor GS-9132/ACH-806 Protease inhibitor Idenix Roche Japan Tobacco/Akros Wyeth/Viropharma Vertex Schering-Plough Gilead/Achillion Phase IIb Phase I Phase I/II Phase Ib Phase II Phase II Phase I HCV therapy should evolve to a combination of oral, small molecules the best from each class of drugs 12 Source: Company Research 12
13 Chronic HCV Market Innovation Drives More Patients to Be Treated Global HCV Market Sustained Viral Response Rate Pegylated Interferon + RBV SVR: 54% 60% Global Sales ($MM) Interferon 24 Weeks SVR: 12% Interferon 48 Weeks SVR: 20% Interferon + RBV SVR: 41% 50% 40% 30% 20% 10% Sustained Viral Response Rate % Q Q Q Q Q Q Q Q Q Q Q Q S ources: Schering-Plough Quarterly Reports, Hoffman La Roche Quarterly Reports, InterMune Quarterly Reports Credit Suisse First Boston: Hepatitis C Market-Competition Intensifies, March
14 Valopicitabine (NM283) Clinical Development Potential First-to-Market Direct HCV Antiviral Drug Treatment-refractory Patients Phase IIb trial - ongoing 190 HCV genotype 1, treatmentrefractory patients enrolled Up to 72 weeks of treatment Due to higher proportion of gastrointestinal side effects at the 800 mg/day dosing level, 800 mg/day dose arms reduced to 400 mg/day 93% of patients from original 178 ITT population will have complete data per previous protocol Treatment-naïve Patients Phase IIb trial - ongoing 174 HCV genotype 1, treatmentnaïve patients enrolled 48-weeks of treatment Due to higher proportion of gastrointestinal side effects at the 800 mg/day dosing level, 800 mg/day dose arms reduced to 200 mg/day or 400 mg/day 88% of patients from original 173 ITT population will have complete data per previous protocol Valopicitabine is an investigational compound for the treatment of hepatitis C that is currently being evaluated in ongoing clinical trials. The most commonly occurring adverse events are gastrointestinal side effects. For most of the patients experiencing gastrointestinal side effects, the side effects (nausea, vomiting, and occasionally diarrhea) are generally mild to moderate, transient, and resolve while remaining on treatment. However, recent data indicate that at the 800 mg/day dosing level, while most patients still report only mild side effects, a higher proportion report moderate or severe intensity to the gastrointestinal side effects compared to observations at the 200 to 400 mg/day dosing level, and may result in treatment discontinuation
15 Valopicitabine Phase IIb Treatment-Naïve Trial Interim Results at Week 12 Demonstrate Convergence of Activity Serum HCV RNA A B C D E No. of Patients Wk 12 + NM NM NM NM NM (Mean Log 10 Change from Baseline) Weeks B 3.93 log E 3.99 log A 4.27 log C 4.32 log D 4.46 log 15 15
16 Evidence for Antiviral Synergy: NM283 + pegifn Predicted and Observed Viral Load Reductions, Week mg valopicitabine 800 mg valopicitabine peg-ifnα initiated 0 0 Change from Baseline in HCV RNA log NM283 Mono (001) Peg-IFN Mono (006) 283+Peg-IFN (Hyp. Add.) 283+Peg-IFN (Obs 006) Change from Baseline in HCV RNA log Predicted Observed Study Day Study Day 16 16
17 Valopicitabine Phase IIb Treatment-Naïve Trial Convergence of Activity Demonstrated at Weeks 12 and 16 Interim Results Week 12 Results Partial Week 16 Results Group Reduction from Baseline (mean log 10 IU/mL) EVR Rate PCR Negative (20 copies) PCR Negative (600 copies) Reduction from Baseline (mean log 10 IU/mL) PCR Negative (20 copies) PCR Negative (600 copies) A % 60% 70% % 83% B % 45% 71% % 73% C % 48% 77% % 76% D % 67% 77% % 80% E % 52% 65% % 67% Pooled C, D & E % 56% 73% % 74% 17 17
18 Valopicitabine Phase IIb Study in Treatment- Naïve Patients: Safety Summary GI side effects common with initial dosing, usually mild-moderate; lessen within 1-2 weeks in 70-80% of affected patients, typically manageable with continued treatment 32 of 173 (18%) patients discontinued by Week (14%) for adverse events, mostly for GI side effects only 2 patients in 200 mg cohort discontinued 9 SAEs reported through April 1, attributed to NM283 or NM283+pegIFN: dehydration with renal insufficiency and pancreatitis; hyponatremia/hypokalemia; and dehydration with acute gastroenteritis 2 occurred in 800 mg/day arms; 1 in 200 mg/day arm 6 non-attributable: eye infection, flu with dehydration, CHF/diabetes, chest pain, numbness in arm/confusion, burn All patients recovered Grade 3/4 lab abnormalities Most were attributable to peg-ifnα ( WBC, ANC, platelets) 9 patients with Grade 3/4 AST and 2 patients with Grade 3/4 lipase elevation, all in 800 mg treatment groups 18 18
19 Valopicitabine: Development Plan Within next six months, Idenix will continue to gain additional safety and efficacy data: Ongoing phase IIb clinical trials Valopicitabine/ribavirin drug-drug interaction study to begin in 2Q06 Potential additional dose-ranging data Data from these trials will provide meaningful safety and efficacy data and will further define optimal dosing regimen and phase III development plan Evaluate additional populations: HCV/HIV coinfected patients 19 19
20 Cash Flow 2005 / 2006 Summary ($ in millions) 9/30/05 Cash Balance, incl. marketable sec. $ Q 05 Cash Flow Net Proceeds from Follow-On Offering ($18.6) $ /31/05 Cash Balance, incl. marketable sec. $ Q 06 Cash Flow Valopicitabine license fee ($22.3) $25.0 3/31/06 Cash Balance, incl. marketable sec. $244.8 Strong Cash Position 20 20
21 2006 Milestones Expected to Drive Value 21 Telbivudine Global regulatory filings by Novartis 1Q Data from phase IIIb studies Telbivudine vs. adefovir 1H Lamivudine switch 2H 2-year GLOBE study data 2H Anticipated approval US NDA 2H Valopicitabine (NM283) In-licensing decision by Novartis 1Q Phase IIb in treatment-refractory population 24-week data Spring Phase IIb in treatment-naïve population 12-week data Spring 24-week data Fall Initiate ribavirin drug-drug interaction study 1H Pre-clinical File IND for HIV drug candidate 2H 21
22 Idenix Pharmaceuticals: Building a Leading Antiviral Franchise Investor Contact: Amy Sullivan Executive Director, Corp. Comm investor@idenix.com
Idenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen and Company 7 th Annual Global Healthcare Conference November 7, 2006 Jean-Pierre Sommadossi, Ph.D. Chairman and CEO Safe Harbor This
More informationHandelsbanken November Bertil Samuelsson VP Discovery Research Rein Piir CFO / IR
Handelsbanken November 18 2009 Bertil Samuelsson VP Discovery Research Rein Piir CFO / IR Pipeline Project Indication(s) Partners/- date of Explorati Optimiz agreement Terms Medivir's markets ve phase
More informationMedivir at. Avanza s Företagsdag 10 december Lars Adlersson, CEO Börje Darpö, VP Development
Medivir at Avanza s Företagsdag 10 december 2008 Lars Adlersson, CEO Börje Darpö, VP Development Medivir contact rein.piir@medivir.se www.medivir.com Medivir Key achievements 2008 Strong phase IIa data
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationM (SAPPHIRE-II)
PRESS RELEASE AbbVie Demonstrates 96 percent SVR 12 in its Phase III Study of Treatment- Experienced Patients with Genotype 1 Hepatitis C Results further confirm phase II studies, with consistent virologic
More informationHCV MEDICATIONS & Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati
HCV MEDICATIONS & THERAPEUTIC TRIALS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati DISCLOSURES Active or Within 12 Months Research
More informationViral hepatitis in reproductive health. Pierre Jean Malè. Training in Reproductive Health Research - Geneva 2006
Viral hepatitis in reproductive health Pierre Jean Malè Training in Reproductive Health Research - Geneva 2006 15.03.2006 HBV and HCV treatment Pierre-Jean Malè MD 15.03.2006 Global Impact of Hepatitis
More informationHorizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Tenofovir disoproxil fumarate for hepatitis B April 2007 This technology summary is based on information available at the time of research
More informationRNAi Therapy for Chronic HBV Infection
RNAi Therapy for Chronic HBV Infection Bill Symonds, PharmD Chief Development Officer October 2017 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking
More informationEiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results
Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results Data from Multi-center, International LOWR HDV (LOnafarnib With Ritonavir in HDV) Phase 2 Program to be Presented at AASLD 2016 Eiger
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationBuilding a Franchise in HDV. Pegylated Interferon Lambda-1a
Building a Franchise in HDV Sarasar (lonafarnib) Pegylated Interferon Lambda-1a Forward-Looking Statements This presentation and the oral commentary contain forward-looking statements that involve substantial
More informationA Leading HBV Therapeutics Company. Corporate Overview August 2017
A Leading HBV Therapeutics Company Corporate Overview August 2017 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking statements within the meaning of
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationTargeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates
Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates Richard Colonno Executive Vice President and Chief Scientific Officer of Virology Operations 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationRichard Colonno Executive Vice President and Chief Scientific Officer of Virology Operations
Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates Richard Colonno Executive Vice President and Chief Scientific Officer of Virology Operations 1 CAUTIONARY NOTE REGARDING FORWARD-
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationSpecifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C
Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Zobair M. Younossi, MD, MPH, FACP, FACG Medscape Gastroenterology. 2007; 2007 Medscape Posted 06/01/2007 Introduction
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationDon t interfere My first choice is always nucs!
Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationScottish Medicines Consortium
Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment
More informationLehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer
Lehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer 2005 Adolor Corporation. All rights reserved. Safe Harbor Statement This
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationA collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C
A collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C Jefferies Health Care Conference June 2013 Charlotte Edenius, EVP Development
More informationentecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd
entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationCredit Suisse 27 th Annual Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE Credit Suisse 27 th Annual Healthcare Conference November 14, 2018 Forward-Looking Statements and Adjusted Financial Information This
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationV.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain, R. Bailey, A. Neumann, P. Cronin, J. McHutchison, E. Pulkstenis, M.
COMPARABLE ANTIVIRAL RESPONSE RATES WITH ALBINTERFERON ALFA-2B DOSED AT Q2W OR Q4W INTERVALS IN NAIVE SUBJECTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C V.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain,
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationBristol-Myers Squibb. HCV Full Development Portfolio Overview. Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013
Bristol-Myers Squibb HCV Full Development Portfolio Overview Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013 1 BMS Agents in Clinical Development: DAAs and INF Lambda Lambda
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationMANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT. Professor Salimur Rahman
MANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT Professor Salimur Rahman Department of Hepatology, BSMMU President, Association for the study of the liver, Dhaka,
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationIs there a need for combination therapy? No. Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain
Is there a need for combination therapy? No Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain No, No and No EASL Update HBV Guidelines 2012 The most potent drugs with the optimal
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationInterferon Side Effects and The Future of Interferon Sparing Regimens. Todd Wills, MD ETAC Infectious Disease Specialist
Interferon Side Effects and The Future of Interferon Sparing Regimens Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL FEBRUARY 15,
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationTreatment guidance for Chronic Hepatitis C Infection
Treatment guidance for Chronic Hepatitis C Infection A meeting of the network was held on 11 April 2008 at which the current evidence base for hepatitis C was reviewed. These guidelines have been produced
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationTenofovir as a drug of choice for the chronic hepatitis B treatment
EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis
More informationA Leading HBV Therapeutics Company Corporate Overview March 2018
A Leading HBV Therapeutics Company Corporate Overview March 2018 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationPegylated Interferons and Ribavirins
Pegylated Interferons and Ribavirins Goal(s): Cover drugs only for those clients where there is evidence of effectiveness and safety Length of Authorization: 16 weeks plus 12-36 additional weeks or 12
More informationARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C
ARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C OCTOBER 11, 2017 NASDAQ: ARDX FORWARD-LOOKING STATEMENTS To the extent that statements contained in this presentation are not descriptions
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationAll Active Events EphMRA ATC Code J5B1 (Viral Hepatitis Products)
Helping you find value in the pharma and biotech sector All Active Events EphMRA ATC Code J5B1 (Viral Hepatitis Products) 13 May 2015 Terms and Conditions All intellectual property rights in this report
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationPrimary Care for Hepatitis B and C:
Primary Care for Hepatitis B and C: Clinical Tools for Efficient Management Estimated 17 Million Persons With HCV Infection Worldwide 3-4 million newly infected each yr worldwide Advances in Internal Medicine
More informationDiscovery of Potent, Highly Selective, Broad Spectrum Antivirals
Discovery of Potent, Highly Selective, Broad Spectrum Antivirals Fred Hutch/Merck Infectious Disease Summit May 10, 2018 Sam Lee, Ph.D. 1 Forward Looking Statements This presentation contains forward-looking
More informationScottish Medicines Consortium
Scottish Medicines Consortium pegylated interferon α 2b (ViraferonPeg ), 50, 80, 100, 120 or 150 micrograms powder for solution for injection in pre-filled pen, in combination with ribavirin (Rebetol ),
More informationGlecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
Phase 3 Treatment Naïve or Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 *ENDURANCE-2: Study Features ENDURANCE-2 Trial Design: Randomized, double-blind, placebo-controlled
More informationEmerging Approaches for the Treatment of Hepatitis C Virus
Emerging Approaches for the Treatment of Hepatitis C Virus Gap Analysis 1 Physicians may not be sufficiently familiar with the latest guidelines for chronic HCV treatment, including the initiation and
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationBIOTRON TO PRESENT AT AUSTRALIA BIOTECH INVEST 2013
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 28 October 2013 The Manager Companies ASX Limited 20
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationJP Morgan Healthcare Conference. January 8, 2007
JP Morgan Healthcare Conference January 8, 2007 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationGish RG and AC Gadano. J Vir Hep
Treatment in Hepatitis B and C There are options! Karen F. Murray, MD Professor of Pediatrics Director, Hepatobiliary Program Seattle Children s Hepatitis B Virus Epidemiology and natural history 400
More informationDelta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne
Delta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne Delta hepatitis treatment in 2018 Currently, Peg-IFNα 180 µg/wk is the only effective treatment
More informationHepatitis C & HIV Coinfection and Brief Advances on Hepatitis B & HIV: The Evidence and New Proposals
Hepatitis C & HIV Coinfection and Brief Advances on Hepatitis B & HIV: The Evidence and New Proposals Douglas G. Fish, MD Albany Medical College April 3, 2009 Cali Colombia Objectives HCV Epidemiology
More informationN A S D A Q : E V F M
N A S D A Q : E V F M Jefferies Global Healthcare Conference June 7, 2018 Disclaimer This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform
More informationNovember 2013 AASLD Investor Event 4 November
November 2013 AASLD Investor Event 4 November Maris Hartmanis, President and CEO Charlotte Edenius, EVP Development Bertil Samuelsson, CSA Rein Piir, EVP Corporate Affairs & IR Corporate presentation,
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More information2.0 Synopsis. ABT-450/r, ABT-267 M Clinical Study Report R&D/17/0539. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-450, ritonavir, ABT-267, ribavirin, pegylated interferon Name of Active Ingredient: ABT-450, Ritonavir, ABT-267, Ribavirin, Pegylated interferon Individual
More informationPath to Value and Profitability
Path to Value and Profitability June 4, 2015 Tim Clackson, Ph.D. President of R&D, Chief Scientific Officer ARIAD Pharmaceuticals, Inc. Elsa So Non-small cell lung cancer ARIAD clinical trial patient Some
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More information